December 8, 2025BloodOpen Access

Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

JWJia Wang

Discussion

Member takes

Implication

Observational analysis revealed an overall response rate of 87.5% in relapsed/refractory B-cell lymphoma, indicating glofitamab's potential benefits and manageable side effects.

Key Points

The overall response rate of 87.5% was observed in patients treated with glofitamab for relapsed/refractory B-cell lymphoma.
Complete response was achieved in 37.5% of patients after multiple treatment cycles, with early T cell exhaustion noted.
Patients experienced adverse events like neutropenia and cytokine release syndrome, mainly manageable and reversible with treatment.
Findings suggest that monitoring T cell dynamics may help predict treatment outcomes in B-cell lymphoma patients.

Cite This Study

Jia Wang (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3d8 https://doi.org/10.1182/blood-2025-7266

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis revealed an overall response rate of 87.5% in relapsed/refractory B-cell lymphoma, indicating glofitamab's potential benefits and manageable side effects.

Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider